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Background: The impact of the COVID-19 mammography screening hiatus as well as of post-hiatus efforts pro
moting restoration of elective healthcare on breast cancer detection patterns and stage distribution is unknown.
Methods: Newly diagnosed breast cancer patients (2019–2021) at the New York Presbyterian (NYP) Hospital
Network were analyzed. Chi-square and student’s t-test compared characteristics of patients presenting before
and after the screening hiatus.
Results: A total of 2137 patients were analyzed. Frequency of screen-detected and early-stage breast cancer
declined post-hiatus (59.7%), but returned to baseline (69.3%). Frequency of screen-detected breast cancer was
lowest for African American (AA) (57.5%) and Medicaid patients pre-hiatus (57.2%), and this disparity was
reduced post-hiatus (65.3% for AA and 63.2% for Medicaid).
Conclusions: The return to baseline levels of screen-detected cancer, particularly among AA and Medicaid patients
suggest that large-scale breast health education campaigns may be effective in resuming screening practices and
in mitigating disparities.

1. Introduction

worsen pre-existing disparities in cancer outcomes.4,5 Pandemic severity
was extensive in metropolitan New York, necessitating some of the
strictest and lengthiest shelter-in-place mandates. New York-based
hospital networks therefore implemented large-scale public education
campaigns to promote resumption of routine health maintenance, such
as cancer screening, following lifting of the restrictions. We sought to
evaluate the impact of the restrictions and post-hiatus healthcare pro
motion efforts on breast cancer detection patterns and stage distribution
in a large metropolitan New York healthcare system serving the diverse
communities of Manhattan, Queens, and Brooklyn.

Due to the surge of COVID-19 cases in March of 2020 in the United
States, a several months-long hiatus was placed on elective healthcare
such as screening mammography programs in support of shelter-in-place
mandates and diversion of medical resources to pandemic
management.1–3
Negative effects of the pandemic have been disproportionately se
vere on minority racial/ethnic communities, and these socioeconomic
effects coupled with the cancer screening hiatus have been projected to
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2. Material and methods

3. Results

2.1. Patient population

A total of 2298 unique patients were discussed at MDC across the
NYP network from January 1, 2019 to June 30, 2021.11 patients lacked
clinical stage, 19 patients presented with locoregional recurrence, and
21 patients were excluded as their self-reported race was unknown
(Fig. 1). A total of 1150 patients presented pre-hiatus, and 987 posthiatus, with 110 patients presenting during the peak of the COVID-19
pandemic from March 15, 2020 to June 15, 2020. The final study pop
ulation was ultimately comprised of 2137 unique patients presenting
before and after the mammography screening hiatus (Fig. 1).

This retrospective analysis was approved by the Weill Cornell Med
icine (WCM) institutional review board. For this type of study no formal
consent was required. This database and its analysis were performed
with the ethical standards of the institutional research committee and
the Helsinki declaration.
All patients with a new diagnosis of breast cancer discussed at
multidisciplinary tumor board conferences (MDC) across the New York
Presbyterian (NYP) network from January 1, 2019 to June 30, 2021
were evaluated. The three network sites include New York Presbyterian
– Weill Cornell Medical Center in Manhattan, New York Presbyterian
Brooklyn Methodist Hospital (BMH) in Brooklyn, and New York Pres
byterian Queens (NYPQ). MDC cases are representative of nonmetastatic newly diagnosed breast cancer cases at each site and occur
on a weekly or biweekly basis. While metastatic breast cancer cases
typically are not discussed, these cases are much less frequently screendetected. Of note, BMH MDC meetings were implemented in January
2020; therefore, BMH data from 2019 was excluded from this analysis.
The New York City mammography screening hiatus was imple
mented from March 15, 2020 to June 15, 2020. Patients were therefore
stratified into two intervals based upon date of diagnosis. Pre-hiatus
interval cases included patients diagnosed between January 1, 2019
and March 14, 2020; post-hiatus patients were diagnosed between June
16, 2020 and June 30, 2021.
The NYP hospital network launched a large-scale “Welcome Back
Safely” campaign following lifting of the hiatus as a strategy to restore
public confidence in resuming routine health maintenance practices
while continuing to comply with social distancing measures.6 Addi
tionally, the NYP network hosted 246 cancer awareness events across
the enterprise, including 165 health education events and 53 screening
events. Of note, these events included 50 bilingual events in English and
Spanish, 38 events in Spanish only, and 4 events in Chinese. We there
fore also sought to examine trends in breast cancers diagnosed during
three sequential short-term periods within the post-hiatus interval. The
timeframes for these three intervals were chosen to distribute the
number of days in each evenly.

3.1. Impact of the screening hiatus on patient population across the
network
Table 1 demonstrates characteristics of patients presenting prior to
and after the COVID-19 related mammography screening hiatus (n =
2317). Statistically significant differences in frequency by hospital site
were noted pre- and post-pandemic (p < 0.001); for example, proportion
of cases at BMH were 4.17% pre-hiatus and increased to 13.17% posthiatus reflecting the later establishment of the Brooklyn-based multi
disciplinary breast program compared to the other two network sites.
The Brooklyn patient population also featured a higher proportion of AA
patients, contributing to the overall network-wide increase in AA pa
tients noted from 13.57% pre-hiatus to 17.53% post-hiatus (p < 0.001).
A borderline significant difference in age was seen with younger patients
presenting post-hiatus (59.52 years pre-hiatus vs. 58.53 years posthiatus; p = 0.089). There was also a borderline significant difference
in the insurance status of patients with more Medicaid and fewer
Medicare patients seen post-hiatus (p = 0.072). The proportions of pa
tients with screen-detected breast cancer, early stage (T1) or in situ
(DCIS) disease, and node-negative disease was similar in the pre-hiatus
and post-hiatus intervals.
3.2. Impact of the COVID-19 screening hiatus on individual network sites
Table 2 demonstrates the impact of the COVID-19 screening hiatus
on patient populations at each of the three network sites. Site specific
differences are seen regarding self-reported race, with BMH seeing the
largest percentage of AA patients both pre- and post-hiatus (56.3% pre
and 54.6% post) and NYPQ seeing the largest population of AS patients
pre- and post-hiatus (44.3% pre and 45.5% post). Manhattan and
Queens also observed differences in the distribution of patients by race,
driven largely by an increase in OTH patients post-hiatus (3.7% pre vs.
8.4% post at WCM and 15.5% pre vs. 23.1% post at NYPQ); however,
this was only statistically significant at Manhattan. There was no sig
nificant change after the hiatus with respect to payor status within each
individual site. The Manhattan site had the lowest proportion of
Medicaid patients both pre- and post-hiatus (11.0% and 13.3% at WCM
v. 29.2% and 21.5% at BMH, 21.1% and 29.5% at NYPQ). Notably, the
Queens site was comprised of more Medicaid patients overall compared
to Manhattan but maintained a very high rate of screen-detected breast
cancer (74.4% pre and 77.3% post). Over time, only BMH displayed a
significantly increased percentage of patients with screen-detected dis
ease (35.4% pre v. 63.8% post; p < 0.001) after the hiatus, as well as an
increase of T1 breast cancer (27.1% pre v. 43.1%; post p = 0.052) and a
significant increase in clinically node-negative patients (64.6% pre v.
84.6% post; p = 0.003). The Brooklyn-based patterns, however, reflect a
relatively small overall volume of breast cancer patients seen in the prehiatus interval due to the initiation of its multidisciplinary breast pro
gram only a few months prior to the start of the hiatus.

(i) post-hiatus I: June 16, 2020–October 31, 2020;
(ii) post-hiatus II: November 1, 2020–February 28, 2021; and
(iii) post-hiatus III: March 1, 2021–June 30, 2021.
Patients were eligible for inclusion if they presented with a new
diagnosis of stage 0-III breast cancer and were presented at MDC.
Clinical information regarding patient age at diagnosis, self-reported
race/ethnicity, insurance status, date of diagnosis (defined as date of
biopsy-proven malignancy), mode of detection (mammography screendetected or MRI screen-detected), and clinical T and N stage were
abstracted from the medical record. Self-reported race and ethnicity
data were utilized to categorize patients into five racial groups to
evaluate for disparities: Asian American (AS), non-Hispanic white
(NHW), African American/Black (AA), Hispanic/LatinX (HISP), and
Other (OTH). Patients in the OTH category included patients who selfreported as Other (67.49%), Multiracial (3.94%), or biracial (28.57%).
2.2. Statistical analysis
Statistical analyses were performed to compare clinical and demo
graphical characteristics of patients presenting prior to and after the
breast cancer screening hiatus. Additionally, patients were stratified by
self-reported race and insurance status to investigate disparities. Chisquare test was used to compare categorical variables and student’s ttest was done for continuous variables. All analyses were carried out
utilizing Stata IC 16.1 (StataCorp, College Station, TX).

3.3. Disparities in screen-detected breast cancer
Table 3 demonstrates the percentage of patients with screen-detected
breast cancer before and after the screening hiatus stratified by race,
2
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Fig. 1. Patient inclusion and reasons for exclusion.

location, and insurance status. Across all race groups, AA patients had
the lowest percentage of screen-detected breast cancers pre-hiatus
(57.7% v. 69.2% NHW, 63.9% HISP, 67.3% AS, and 72.4% OTH); this
proportion increased in the post-hiatus interval, becoming comparable
to the rates observed in the other groups, although these differences
were not statistically significant. Similarly, Medicaid patients had less
screen-detected disease pre-hiatus, but this percentage improved posthiatus (p = 0.24). NYPQ consistently had higher proportions of
screen-detected patients compared to the other sites both pre- and posthiatus.

pattern correlated with rising proportions of patients presenting with T1
tumors (Post-hiatus I: 46.1%; Post-hiatus II: 53.8%; Post-hiatus III:
58.5%; p = 0.006) and node-negative disease (Post-hiatus I: 84.2%;
Post-hiatus II: 89.7%; Post-hiatus III: 89.5%; p = 0.043); however, the
proportion of patients presenting with in situ disease remained rela
tively stable over time (Post-hiatus I: 21.9%; Post-hiatus II: 25.9%; Posthiatus III: 21.3%; p = 0.32) (Fig. 2).
3.5. Disparities in screen-detected breast cancer by insurance status
Table 4 demonstrates the percentage of patients with screen-detected
breast cancer stratified by insurance status. Overall, for all patients
regardless of site, more than 60% of NHW patients had screen-detected
breast cancer (66.9% at WCM, 63.2% at BMH and 73.6% at NYPQ). At
NYPQ, more than 70% of patients had screen-detected breast cancer
regardless of race (73.6% for NHW, 78.4% for AA, 86.0% for HISP,
75.2% for AS, and 72.3% for OTH). At BMH, patients had relatively low
(<60%) rates of screen-detected disease regardless of race, except for
NHW and OTH; however, only 7 patients were in the OTH category for

3.4. Comparison of patients during post-hiatus intervals
Fig. 2 displays patients presenting after the mammography screening
hiatus was lifted, stratified by post-hiatus interval. The percentage of
screen-detected breast cancers was lowest during the immediate interval
after the screening hiatus (June 16, 2020–October 31, 2020) and grad
ually returned to baseline over the ensuing intervals (Post-hiatus I:
59.7%; Post-hiatus II: 69.4%; Post-hiatus III: 69.3%; p = 0.009). This
3
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Table 1
Patients presenting across the NYP network before and after the COVID-19 related mammography screening hiatus (Pre-hiatus defined as date of diagnosis from
January 1, 2019 to March 14, 2020 and Post-hiatus June 16, 2020 to June 30, 2021); WCM = Weill Cornell Medicine; BMH = Brooklyn Methodist Hospital; NYPQ =
New York Presbyterian Queens; NHW = Non-Hispanic White; AA = African American/Black; HISP = Hispanic/LatinX; AS = Asian American; OTH = Other; DCIS =
Ductal carcinoma in situ
*p-value reflects comparison of pre-hiatus vs. post-hiatus.
Location
Race/Ethnicity

Mean Age
Insurance

WCM n = 1320
BMH N = 178
NYPQ N = 639
NHW N ¼ 904
AA N ¼ 329
HISP N ¼ 207
AS N ¼ 494
OTH N ¼ 203

Medicaid N = 358
Medicare N ¼ 738
Private N ¼ 1035
Other N = 6
Screen-detected breast cancer N ¼ 1419
T1 breast cancer N ¼ 1114
DCIS N = 497
Node-negative N ¼ 1879

Overall N = 2137

Pre-Hiatus N = 1150

Post-Hiatus N = 987

p-value*

1320 (61.77%)
178 (8.33%)
639 (29.90%)
904 (42.30%)
329 (15.39%)
207 (9.69%)
494 (23.12%)
203 (9.50%)
59.06
358 (16.75%)
738 (34.58%)
1035 (48.43%)
6 (0.28%)
1419 (66.40%)
1114 (52.13%)
497 (23.26%)
1879 (87.93%)

727 (63.22%)
48 (4.17%)
375 (32.61%)
504 (43.83%)
156 (13.57%)
122 (10.61%)
281 (24.43%)
87 (7.57%)
59.52
173 (15.04%)
419 (36.34%)
555 (48.26%)
3 (0.3%)
769 (66.87%)
597 (53.59%)
269 (23.39%)
1014 (88.17%)

593 (60.01%)
130 (13.17%)
264 (26.75%)
400 (40.53%)
173 (17.53%)
85 (8.61%)
213 (21.58%)
116 (11.75%)
58.53
185 (18.74%)
319 (32.32%)
480 (48.63%)
3 (0.3%)
650 (65.86%)
517 (46.41%)
228 (23.10%)
865 (87.64%)

<0.001

<0.001

0.089
0.072

0.62
0.83
0.87
0.71

Table 2
Impact of the COVID-19 mammography screening hiatus on the three NYP network sites; WCM = Weill Cornell Medicine; BMH = Brooklyn Methodist Hospital; NYPQ
= New York Presbyterian Queens; NHW = Non-Hispanic White; AA = African American/Black; HISP = Hispanic/LatinX; AS = Asian American; OTH = Other.
WCM

Race/
Ethnicity

NHW N ¼ 904
AA N ¼ 329
HISP N = 207
AS N = 494
OTH N ¼ 203
Insurance
Medicaid N =
358
Medicare N ¼
738
Private N =
1035
Other N = 6
Screen-detected breast cancer
N ¼ 1419
T1 breast cancer N ¼ 1114
Node-Negative N ¼ 1879

BMH

NYPQ

Pre-Hiatus N
= 727

Post-Hiatus N
= 593

pvalue

Pre-Hiatus N
= 48

Post-Hiatus N
= 130

p-value

Pre-Hiatus N
= 375

Post-Hiatus N
= 264

pvalue

419 (57.6%)
85 (11.7%)
86 (11.8%)
110 (15.1%)
27 (3.7%)
80 (11.0%)

337 (56.8%)
72 (12.1%)
57 (9.6%)
77 (13.0%)
50 (8.4%)
79 (13.3%)

0.005

11 (22.9%)
27 (56.3%)
3 (6.3%)
5 (10.4%)
2 (4.2%)
14 (29.2%)

27 (20.8%)
71 (54.6%)
11 (8.5%)
16 (12.3%)
5 (3.8%)
28 (21.5%)

0.98

74 (19.7%)
44 (11.7%)
33 (8.8%)
166 (44.3%)
58 (15.5%)
79 (21.1%)

36 (13.6%)
30 (11.4%)
17 (6.4%)
120 (45.5%)
61 (23.1%)
78 (29.5%)

0.052

235 (32.3%)

165 (27.8%)

18 (37.5%)

57 (43.8%)

166 (44.3%)

97 (36.7%)

410 (56.4%)

347 (58.5%)

16 (33.3%)

44 (33.8%)

129 (34.4%)

89 (33.7%)

2 (0.3%)
473 (65.1%)

2 (0.3%)
363 (61.2%)

0.15

0 (0%)
17 (35.4%)

1 (0.8%)
83 (63.8%)

<0.001

1 (0.3%)
279 (74.4%)

0 (0%)
204 (77.3%)

0.41

383 (52.7%)
643 (88.4%)

329 (55.5%)
516 (87.0%)

0.31
0.43

13 (27.1%)
31 (64.6%)

56 (43.1%)
110 (84.6%)

0.052
0.003

201 (53.6%)
340 (90.7%)

132 (50%)
239 (90.5%)

0.37
0.95

0.27

BMH. When only Medicaid patients were analyzed, there were no sta
tistically significant differences for each race group by site, except at
BMH, where AS patients were less likely to present with screen-detected
disease (p < 0.001) (Table 4).

0.67

0.060

breast cancer screening and breast health awareness programs were an
effective intervention to reduce disparities in early detection.
However, our results must be interpreted with caution. The COVID19 related socioeconomic effects were disproportionately severe in the
AA community, and it is possible that many of the patients most heavily
impacted by the economic toll of the pandemic have yet to return to
clinical breast evaluations. Outreach efforts for screening therefore must
continue. Our data are also limited by the lack of information on patients
presenting with metastatic/Stage IV breast cancer, as our network tri
ages these patients directly to the medical oncology service, while our
MDC program focuses on patients presenting with non-metastatic
disease.
We also noted interesting patterns regarding patients in the OTH
category for racial-ethnic identity, as patients with mixed race/ethnicity
were included in this group. As the American population becomes more
admixed, it will be increasingly important to evaluate the racial/ethnic
identity more precisely, such as by use of Ancestry Informative Markers
to quantify ancestral heritage. These germline genetic patterns may
provide meaningful clues regarding hereditary susceptibility for breast
cancer associated with racial/ethnic identity.
To date, little is known regarding the impact of the COVID-19

4. Discussion
In this study of a large population of breast cancer patients pre
senting to three academic medical centers across the NYP network
during and after the peak of the COVID-19 pandemic, our data document
the plummeting of screen-detected disease during the mammography
hiatus followed by a gradual recovery to pre-hiatus proportions of
screen-detected disease by one year later. We also found no significant
shift occurred in the percentage of patients presenting with clinical T1
and node-negative disease after the hiatus was lifted.
We speculate that promotional efforts to encourage patients to
resume healthcare routines (including cancer screening) in the posthiatus period had a favorable impact on decreasing breast cancer dis
parities, as proportions of mammography screen-detected breast cancers
increased among AA and Medicaid patients compared to their pre-hiatus
rates, reaching incidence comparable to other subsets. This suggests that
4
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program on the incidence of screen-detected tumors, similar to our
study. In this analysis, the incidence of screen-detected breast tumors
decreased by nearly 70% during early 2020 but by August 2020 there
was no indication of a shift toward more advanced stage breast cancers
after screening programs resumed.8 In another study examining the
impact of the two-month mammography screening hiatus in Italy, the
investigators found a decrease in in-situ breast cancer by 10.4%, an
increase of 11.2% of node-positive patients, and a 10.3% increase in
clinical stage III patients. However, the rate of clinical T1, T2, and T3
tumors diagnosed during May to July of 2020 did not significantly differ
from tumors diagnosed in the same period of 2019.9 In another Italian
study that analyzed 432 breast cancer patients undergoing surgery for
breast cancer prior to and during the lockdown, the authors found no

Table 3
Percentage of patients with screen-detected breast cancer pre and post-hiatus,
stratified by race, location, and insurance status; NHW = Non-Hispanic White;
AA = African American/Black; HISP = Hispanic/LatinX; AS = Asian American;
OTH = Other; WCM = Weill Cornell Medicine; BMH = Brooklyn Methodist
Hospital; NYPQ = New York Presbyterian Queens.
No. with Screen-Detected Disease (%)
Race/
Ethnicity

NHW N = 904
AA N ¼ 329
HISP N ¼ 207
AS N ¼ 494
OTH N ¼ 203

Location

WCM N ¼ 1320
BMH N ¼ 178
NYPQ N ¼ 639

Insurance

Medicaid N ¼
358
Medicare N ¼
738
Private N ¼
1035

Pre-Hiatus

Post-Hiatus

p-value

349/504
(69.2%)
90/156
(57.7%)
78/122
(63.9%)
189/281
(67.3%)
63/87 (72.4%)

262/400
(65.5%)
113/173
(65.3%)
51/85 (60.0%)

0.23

144/213
(67.6%)
80/116
(69.0%)
363/593
(61.2%)
83/130
(63.8%)
204/264
(77.3%)
117/185
(63.2%)
225/319
(70.5%)
306/480
(63.8%)

0.94

473/727
(65.1%)
17/48 (35.4%)
279/375
(74.4%)
99/173
(57.2%)
288/419
(68.7%)
382/555
(68.8%)

0.16
0.57

Table 4
Proportion of all payor and Medicaid patients with screen-detected breast cancer
stratified by site and race/ethnicity; NHW = Non-Hispanic White; AA = African
American/Black; HISP = Hispanic/LatinX; AS = Asian American; OTH = Other;
WCM = Weill Cornell Medicine; BMH = Brooklyn Methodist Hospital; NYPQ =
New York Presbyterian Queens
*p-value denotes comparison of patients within each racial group across sites,
regardless of insurance status
**p-value denotes comparison of only Medicaid patients within each racial
group across sites.

0.59
0.15
<0.001
0.41
0.24
0.60
0.084

NHW
AA

pandemic on the diagnostic stage distribution of breast cancer patients
in the United States. International data have shown mixed results with
respect to patients presenting with later stage disease as a result of
temporary suspensions in screening and national lockdowns. For
example, one study utilizing data from the Netherlands Cancer Registry
compared patients diagnosed during weeks 2–17 of 2020 to the same
period of 2018 and 2019. Eijkelboom et al. found a shift in cancer
incidence, with reduced incidence of all tumor stages, except for stage
IV, from 2018/2019 to 2020.7 More recently, the investigators analyzed
the impact of the suspension of the Dutch national screening breast

HIS
AS
OTH

WCM
BMH
NYPQ
WCM
BMH
NYPQ
WCM
BMH
NYPQ
WCM
BMH
NYPQ
WCM
BMH
NYPQ

Overall

p-value*

Medicaid

p-value**

506/756 (66.9%)
24/38 (63.2%)
81/110 (73.6%)
89/157 (56.7%)
56/98 (57.1%)
58/74 (78.4%)
78/143 (54.5%)
8/14 (57.1%)
43/50 (86.0%)
112/187 (59.9%)
6/21 (28.6%)
215/286 (75.2%)
51/77 (66.2%)
6/7 (85.7%)
86/119 (72.3%)

0.31

31/66 (47%)
3/8 (37.5%)
9/14 (64.3%)
15/32 (46.9%)
8/19 (42.1%)
6/10 (60%)
11/23 (47.8%)
3/4 (75%)
9/11 (81.8%)
19/28 (67.9%)
1/8 (12.5%)
85/104 (81.7%)
4/10 (40%)
2/3 (66.7%)
10/18 (55.6%)

0.40

0.004

<0.001

<0.001

0.44

0.65
0.14

<0.001

0.63

Fig. 2. Characteristics of patients presenting before and after the mammography screening hiatus was lifted, stratified by post-hiatus interval (Post-hiatus I: patients
diagnosed between June 16, 2020–October 31, 2020; Post-hiatus II: November 1, 2020–February 28, 2021; Post-hiatus III: March 1, 2021–June 30, 2021); DCIS =
Ductal carcinoma in situ
*p-value denotes comparison of Post-Hiatus I, Post-Hiatus II and Post-Hiatus III.
5
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difference in the distribution of pathologic T stage but did see a statis
tically significant increase in node-positivity, which is likely to impact
outcomes.10,11 Recent data from the Mayo Clinic of 390 patients
pre-COVID and 81 patients post-COVID found nearly identical rates of
breast cancer detection by imaging before and after the pandemic (66%
vs. 65% after; p = 0.80). However, they found that the percentage of
patients presenting with clinical stage II-IV was 42% during-COVID
compared to 37% pre-COVID, although this difference was not statisti
cally significant (p = 0.27).10
While the aforementioned studies suggest a significant shift in the
presentation of breast cancer as a result of the pandemic, all of these
studies are limited by the inclusion of patients over a narrow period of
time. Our study is the first to our knowledge that examines patients in a
large, racially diverse, metropolitan area, and it spans the course of the
pandemic, including patients presenting in the first half of 2021, coin
ciding with the widespread availability of the COVID-19 vaccine in the
United States.
To further elucidate the return to baseline levels of mammography
screen-detection and stage distribution, patients presenting after the
hiatus was lifted were stratified into three post-hiatus intervals. An in
crease in the proportion of screen-detected breast cancer was seen over
time, from 59.7% during post-hiatus interval I to 69.3% in post-hiatus
interval III. This evolution may be due to several factors, such as pa
tient willingness to resume regular screening, increased confidence due
to widespread availability of the COVID-19 vaccine, and effectiveness of
public health messages to encourage a return to routine health visits. At
our institution, several changes were made at our women’s imaging
centers to accommodate for the anticipated surge in patients seeking
resumption of breast cancer screening in a safe manner after lockdowns
were lifted. For example, weekday hours were extended with screening
appointments opened on weekends and screening mammogram dura
tions were extended from 15 min to 30 min to allow the time for
adequate disinfection of facilities.
The COVID-19 pandemic has been predicted to worsen pre-existing
cancer disparities through several mechanisms that also have led to
disparities seen with COVID-19 infection and mortality.12 While a
reduction in the volume of cancer screenings has been documented, few
studies have examined cancer screenings by race before and after
COVID-19. A recent study examining socioeconomic and racial in
equities in breast cancer screening in Washington state, examining 55,
678 screening mammograms before the pandemic and 27,522 screen
ings after, found an overall reduction in screenings of 49%. When
stratified by race, the largest reduction in the number of breast cancer
screening from 2019 to 2020 was for Hispanic (− 64.2%), American
Indian/Alaska Native (− 60.9%), mixed race (− 56.2%), Native Hawaiian
or Pacific Islander (− 54.5%), Asian (− 54.4%), and Black (− 53.9%)
women compared to White (− 49.2%).13 Another study reported on
trends in breast cancer screening at a safety-net hospital prior to and
during the pandemic, further stratified by intervals according to
regional stay-at-home orders and reopening phases. In their analysis of
9291 screening mammograms from 2019 to 2021, Velazquez and col
leagues found a significant reduction of screening volumes and pro
portion of completed mammograms from pre-COVID to the second
stay-at-home order (defined as December 2020 to January 2021)
across all racial groups; however, the largest absolute reductions were
seen in Black (− 21%) and Latinx (− 20%) women. Furthermore, they
found that the proportion of completed mammograms was lowest
among Black women at all time points.14 Another study by Marcondes
et al. found no significant improvement or worsening of racial and
ethnic disparities for any cancer screening after the hiatus was lifted.15
Our data show similar findings and suggest a trend toward a mitigation
of these disparities.
In our study, we found that pre-pandemic, AA patients had the lowest
percentage of screen-detected breast cancer. However, our data show an
improvement in the rate of screen-detected breast cancer among AA
patients in the post-pandemic interval. One rationale for this effect is the

increase in targeted public health messages provided in and around the
COVID-19 pandemic to increase screening.16 Additionally, the highest
percentage of AA patients are seen at BMH, and the implementation of
BMH MDC in early 2020 may have increased access to care for this
vulnerable patient population.
By analyzing a large population of patients across a racially diverse
area, our study helps to characterize the impact of the COVID-19
pandemic on populations within each borough. New York City is a
unique geographic location in that it is comprised of five boroughs that
are racially and socioeconomically diverse. For example, among Man
hattan, Brooklyn, and Queens, Brooklyn has the highest percentage of
AA individuals, while Queens has the highest percentage of AS.17 These
geographical differences were also observed among our network wide
data, where we saw the highest percentage of AA patients presenting to
our Brooklyn site (55.1%) and the highest percentage of AS patients
presenting to our Queens site (44.8%). Regarding breast cancer burden,
recent New York State Department of Health data also demonstrate
borough-specific differences in both incidence and mortality rates for
breast cancer. For example, Manhattan has the highest incidence rate of
breast cancer at 141 cases per 100,000 females per year, compared to
120.5 in Brooklyn and 121.9 in Queens. Additionally, Queens has the
lowest breast cancer mortality rate at 16.2 deaths per 100,000 females
compared to 20.2 in Brooklyn and 19.8 in Manhattan.18
Breast cancer disparities are driven not only by racial factors but also
by socioeconomic factors.19 Our data show that across our network,
Medicaid patients had less screen-detected disease pre-hiatus, and that
this percentage improved in the post-hiatus interval. Additionally, while
NYPQ has the highest proportion of Medicaid patients, they maintained
a high level of screen-detected breast cancers both before and after the
screening hiatus. These findings suggest that a combination of wide
spread public health campaigns with community engagement efforts to
encourage a resumption of routine screening can succeed at enhancing
early breast cancer detection after a disruptive event.
There are limitations inherent to this retrospective cohort study. Our
data does not contain pathologic staging data but is based on clinical
stage of presenting patients. Additionally, our dataset does not contain
phenotype, which limits the ability to include updated stage according
to the American Joint Committee on Cancer’s eighth edition of the AJCC
Cancer Staging Manual. The primary outcomes we examined were based
on presenting features and do not apply to differences in treatment
outcomes that may also have resulted from the COVID-19 pandemic.
However, by characterizing the clinical presentation of breast cancer
patients prior to and after the screening hiatus, our data provide valu
able insight into the early effects of the pandemic and may be a marker
of success of post-pandemic public health campaigns to encourage a
resumption of routine health care.
5. Conclusions
In this study comprised of over 2000 patients across the NYP network
spanning a broad range of time before and after the peak of the COVID19 pandemic, our data demonstrate an initial decline in the percentage
of early stage and screen-detected breast cancers immediately after the
COVID-19 related mammography screening hiatus, with a resumption of
our baseline levels seen prior to the pandemic by mid-2021. Addition
ally, our data demonstrate that while racial disparities were seen prior to
the screening hiatus, across our network we observed an increase in
screen-detection among both AA and Medicaid patients post-hiatus.
Further studies are needed to characterize the treatment patterns of
patients presenting at the height of the pandemic as well as oncologic
outcomes.
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